258 related articles for article (PubMed ID: 10392633)
21. p53 gene mutations in Barrett's epithelium and esophageal cancer.
Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
[TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
23. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
25. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
27. The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma.
Baumann S; Keller G; Pühringer F; Napieralski R; Feith M; Langer R; Höfler H; Stein HJ; Sarbia M
Int J Cancer; 2006 Jul; 119(2):264-8. PubMed ID: 16477636
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer.
Casson AG; Manolopoulos B; Troster M; Kerkvliet N; O'Malley F; Inculet R; Finley R; Roth JA
Am J Surg; 1994 Jan; 167(1):52-7. PubMed ID: 8311140
[TBL] [Abstract][Full Text] [Related]
29. The p53 and mdm-2 genes in human testicular germ-cell tumors.
Riou G; Barrois M; Prost S; Terrier MJ; Theodore C; Levine AJ
Mol Carcinog; 1995 Mar; 12(3):124-31. PubMed ID: 7893365
[TBL] [Abstract][Full Text] [Related]
30. Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia.
Younes M; Lechago J; Chakraborty S; Ostrowski M; Bridges M; Meriano F; Solcher D; Barroso A; Whitman D; Schwartz J; Johnson C; Schmulen AC; Verm R; Balsaver A; Carlson N; Ertant A
Scand J Gastroenterol; 2000 Feb; 35(2):131-7. PubMed ID: 10720109
[TBL] [Abstract][Full Text] [Related]
31. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.
Tanière P; Martel-Planche G; Maurici D; Lombard-Bohas C; Scoazec JY; Montesano R; Berger F; Hainaut P
Am J Pathol; 2001 Jan; 158(1):33-40. PubMed ID: 11141476
[TBL] [Abstract][Full Text] [Related]
32. p53 mutations and MDM-2 amplification in renal cell cancers.
Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
[TBL] [Abstract][Full Text] [Related]
33. Molecular analysis of p53 tumor-suppressor gene and microsatellites in preneoplastic and neoplastic lesions of the colon and esophagus.
Copelli SB; Mazzeo C; Gimenez A; Casco C; Meiss R; Rubio H; Speroni A; Vanzulli S
Oncol Rep; 2001; 8(4):923-9. PubMed ID: 11410811
[TBL] [Abstract][Full Text] [Related]
34. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
35. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
36. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
37. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Ittmann M; Wieczorek R; Heller P; Dave A; Provet J; Krolewski J
Am J Pathol; 1994 Aug; 145(2):287-93. PubMed ID: 8053489
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
[TBL] [Abstract][Full Text] [Related]
39. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations.
Coggi G; Bosari S; Roncalli M; Graziani D; Bossi P; Viale G; Buffa R; Ferrero S; Piazza M; Blandamura S; Segalin A; Bonavina L; Peracchia A
Cancer; 1997 Feb; 79(3):425-32. PubMed ID: 9028350
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas.
Fléjou JF; Muzeau F; Potet F; Lepelletier F; Fékété F; Hénin D
Pathol Res Pract; 1994 Dec; 190(12):1141-8. PubMed ID: 7540752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
